EFPIA publishes coronavirus pledges
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has again made clear its drive to help tackle the coronavirus pandemic, this time by publishing a series of commitments.
The EFPIA’s three central aims during the crisis are to ensure the safe supply of medicines to patients that need them, research and develop new vaccines, treatments and diagnostics for COVID-19 and partner and support organizations on the ground that are fighting against the virus.
"The commitments we published today, are our industry’s contribution to that collaborative, collective effort to tackle the coronavirus"Jean-Christophe Tellier, EFPIA president and chief executive of Belgian drugmaker UCB (Euronext: UCB), said: “With Europe at the epicenter of the COVID-19 crisis, the researched-based pharmaceutical industry is coming together to commit its resources, expertise and people to the fight against COVID-19.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze